Skip to content
HowShorted

Stoke Therapeutics, Inc. short interest in 2020

In 2020, Stoke Therapeutics, Inc.'s disclosed short interest ran from 4.48% of shares outstanding on 15 Jan 2020 to 10.60% on 31 Dec 2020, a change of +6.12 percentage points. The year's high was 10.77% on 30 Jun 2020 and its low 4.48% on 15 Jan 2020, averaging 8.41% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 48.52 days on 15 Oct 2020. Full history: Stoke Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Stoke Therapeutics, Inc. in 2020

2020 in figures

Start of year
4.48% (15 Jan 2020)
End of year
10.60% (31 Dec 2020)
Change
+6.12 pp
High
10.77% (30 Jun 2020)
Low
4.48% (15 Jan 2020)
Average
8.41%
Highest days to cover
48.52 (15 Oct 2020)
SEC filings marked
8

Every report in 2020

Stoke Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20204.48%12.31
31 Jan 20206.33%10.55
14 Feb 20207.14%16.28
28 Feb 20207.62%19.07
13 Mar 20208.38%10.48
31 Mar 20208.31%7.8410-K filed, results (8-K)
15 Apr 20208.85%15.52
30 Apr 20209.02%28.79
15 May 20209.21%31.0210-Q filed, results (8-K)
29 May 20209.26%36.57
15 Jun 20209.51%28.70
30 Jun 202010.77%15.53
15 Jul 20207.58%23.47
31 Jul 20207.83%20.95
14 Aug 20208.07%30.2210-Q filed, results (8-K)
31 Aug 20208.35%48.31
15 Sep 20208.43%34.42
30 Sep 20208.55%25.34
15 Oct 20208.68%48.52
30 Oct 20208.59%40.81
13 Nov 20208.49%26.2510-Q filed, results (8-K)
30 Nov 20208.82%12.88
15 Dec 20208.86%32.31
31 Dec 202010.60%15.83

See also: Stoke Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.